

PRODUCT INFORMATION



STING R232 variant (human, recombinant)


Item No. 22816

Overview and Properties

| | |
|-------------------------------|--|
| Synonyms: | Endoplasmic Reticulum Interferon Stimulator, ERIS, Mediator of IRG3 Activation, MITA, Mitochondrial Mediator of IRF3 Activation, MPYS, Stimulator of Interferon Genes, Stimulator of Interferon Response cGAMP Interactor 1, STING1, N-Terminal Methionine-Proline-Tyrosine-Serine Plasma Membrane Tetraspanner, TMEM173, Transmembrane Protein 173 |
| Source: | Recombinant N-terminal His-tagged STING catalytic domain purified from <i>E. coli</i> |
| Amino acids: | 138-379 (N-terminal truncation) |
| Uniprot No.: | Q86WV6 |
| Molecular Weight: | 28.8 kDa |
| Storage: | -80°C (as supplied); avoid freeze/thaw cycles by storing protein in aliquots |
| Stability: | ≥2 years |
| Purity: | batch specific (≥80% estimated by SDS-PAGE) |
| Supplied in: | 50 mM HEPES, pH 8.0, 150 mM sodium chloride, 10% glycerol |
| Protein Concentration: | batch specific mg/ml |
| Activity: | Serial dilutions of canonical 3'3'-cGAMP were incubated with 5 µg recombinant human STING R232 variant in 50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, and SYPRO® Orange dye at 4°C. ¹ The reaction was read on a BioRad CFX96 Touch™ Real-Time PCR Detection System at 4-100°C. ² The binding of the ligand stabilizes the protein structure, increasing the melting temperature (T_m), which is detected via a thermal shift assay (TSA), also known as a differential scanning fluorimetry (DSF) assay. ² |


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



Lane 1: MW Markers
Lane 2: STING R232 variant (1 µg)
Lane 3: STING R232 variant (2 µg)
Lane 4: STING R232 variant (4 µg)

Representative gel image shown; actual purity may vary between each batch.



Binding Activity of STING R232 variant (Item No. 22816). STING R232 variant (5 µg) was incubated with serial dilutions of 3'3'-cGAMP (Item No. 17966) and SYPRO® Orange dye. The detected increase in T_m indicates binding.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/29/2024

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Stimulator of interferon genes (STING) is a component of the innate immune response that binds to cyclic dinucleotides, which are bacterial second messengers, leading to activation of NF- κ B and transcription of immunomodulatory genes, including type I interferon (IFN).³⁻⁶ The R232 variant is the most common variant in the human population, found at a frequency of 57.9% in the 1000 Genome Project.⁷ The SNP variant H232 (Item No. 22815) is found at a 13.7% frequency. Various mutations in STING either reduce or increase its activity. Gain-of-function mutations in STING, including R284M (Item No. 23594) and V155M, lead to constitutive activation and enhancement of the type I IFN response.^{7,8} The V155M mutation is associated with a systemic inflammatory condition, including pulmonary fibrosis and autoimmune factors.⁸ Mutations that reduce STING activity include K224R (Item No. 23593), which reduces ubiquitination of STING thereby disrupting its localization within the cell, and the double mutation G230A, R293Q (Item No. 23592), which reduces the IFN response.^{7,9} A T596A mutation present in the mouse strain Goldenticket leads to a complete loss of STING protein and lack of a type I IFN response to infection by *Listeria*.¹⁰

References

1. Diner, E.J., Burdette, D.L., Wilson, S.C., *et al.* The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. *Cell Rep.* **3(5)**, 1355-1361 (2013).
2. Niesen, F.H., Berglund, H., and Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. *Nat. Protoc.* **2(9)**, 2212-2221 (2007).
3. Burdette, D.L., Monroe, K.M., Sotelo-Troha, K., *et al.* STING is a direct innate immune sensor of cyclic-di-GMP. *Nature* **478(7370)**, 515-518 (2011).
4. Sun, L., Wu, J., Du, F., *et al.* Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science* **339(6121)**, 786-791 (2013).
5. Wu, J., Sun, L., Chen, X., *et al.* Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. *Science* **339(6121)**, 826-830 (2013).
6. Konno, H., Konno, K., and Barber, G.N. Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. *Cell* **155(3)**, 688-698 (2013).
7. Yi, G., Brendel, V.P., Shu, C., *et al.* Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. *PLoS One* **8(10):e77846** (2013).
8. Jeremiah, N., Neven, B., Gentili, M., *et al.* Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. *J. Clin. Invest.* **124(12)**, 5516-5520 (2014).
9. Ni, G., Konno, H. and Barber, G.N. Ubiquitination of STING at lysine 224 controls IRF3 activation. *Sci. Immunol.* **2(11):eaah7119** (2017).
10. Sauer, J.D., Sotelo-Troha, K., von Moltke, J., *et al.* The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of sting in the *in vivo* interferon response to *Listeria* monocytogenes and cyclic dinucleotides. *Infect. Immun.* **79(2)**, 688-694 (2011).